← Back to all trials
Completed
NCT05705414
Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis
Conditions: End Stage Renal Disease
Sex: All
Ages: 18 Years – 64 Years
Healthy volunteers: No
Phase: EARLY_PHASE1
Enrollment: 28
Sponsor: The University of Texas Health Science Center at San Antonio
Location: The University of Texas Health Science Center at San Antonio San Antonio Texas
Summary
The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.
Eligibility Criteria
Inclusion Criteria:
1. Male or Female
2. Age 18-64 years
3. Receiving 3 x weekly in clinic hemodialysis for at least 6 months
Exclusion Criteria:
1. Hypersensitivity to amino acid(s) and/or any excipient
2. Clinical documentation of COVID-19
3. Concomitant intake of amino acids supplements
4. Current use or abuse of alcohol, marijuana, narcotic, or other substances
5. Heart failure receiving active management
6. Malignant cancer receiving anticancer therapy
7. Diagnosis of major depressive disorder receiving antidepressants
8. Diagnosis of chronic liver disease
9. Cerebrovascular disease with sequelae
10. Upper limb amputation, osteoarthritis, or degenerative diseases of fingers, carpel tunnel syndrome in the non-fistula or graft hand preventing completion of hand grip strength test.
Source: ClinicalTrials.gov (NCT05705414). StuddyBuddy aggregates publicly available trial information.
